The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMolten Ventures Regulatory News (MVCT)

Share Price Information for Molten Ventures (MVCT)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 44.00
Bid: 43.00
Ask: 45.00
Change: -1.00 (-2.22%)
Spread: 2.00 (4.651%)
Open: 45.00
High: 45.00
Low: 44.00
Prev. Close: 45.00
MVCT Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Portfolio Update

1 May 2024 16:11

RNS Number : 8846M
Molten Ventures VCT PLC
01 May 2024
 

Molten Ventures VCT plc

("Molten", the "VCT" or the "Company")

Legal Entity Identifier: 2138003I9Q1QPDSQ9Z97

Hologic Inc. to acquire Endomagnetics for approx. $310m

 

Molten Ventures VCT plc (LSE: MVCT), a leading Venture Capital Trust investing in and developing high growth digital technology businesses, notes the announcement released by Hologic, Inc. (Nasdaq: HOLX), a global leader in women's health, that it is has signed a definitive agreement to acquire Endomagnetics Ltd. (ÔEndomagÕ). The acquisition, which is subject to regulatory approval as well as working capital and other customary closing adjustments values Endomag at approximately $310m.

https://www.londonstockexchange.com/news-article/GROW/hologic-inc-to-acquire-endomagnetics/16446345

Endomag is a medical technology company, based in Cambridge, devoted to improving the global standard of care in breast cancer. Its products include the Magseed¨ marker for magnetic tissue localisation before surgery, the Magtrace¨ lymphatic tracing injectable for breast cancer staging and the Sentimag¨ platform, which supports both localisation and lymphatic tracing.

Molten VCT first invested in Endomag in July 2018, with investment alongside the balance sheet of Molten Ventures plc (the parent company of the VCT Manager) and Molten VentureÕs separate EIS funds. Follow-on funding was provided to support EndomagÕs continued growth in 2020. The deal values Molten VCTÕs stake in Endomag modestly above its last released September 2023 interim holding value of £8.69million.

In its recent interims, published 14 December 2023, Molten noted ÒWe are hopeful that conditions will begin to improve in 2024 and that we may now be approaching a point in the cycle when excellent investment opportunities in the sectors in which your Company operates are available at attractive prices which can drive strong performance in the futureÓ

David Brock, Chairman of the VCT, commented:

ÒThis transaction demonstrates our ability through our VCT Manager to support innovative businesses as they scale and create value for our shareholders through the cycle.

These proceeds bolster the VCTs distributable reserves which are available for paying dividends and share buybacks. We will provide an update in respect of these anticipated proceeds at the time of the VCTs full year results which are due to be released towards the end of July 2024.Ò

 

-ENDS-

 

About Molten Ventures VCT

 

Molten Ventures VCT is a leading VCT developing and investing in disruptive, high growth technology companies through its VCT Manager Molten Ventures plc (LSE: GROW, Euronext Dublin: GRW).

 

Over the past six years, Molten Ventures plc has scaled its platform to enable access to some of the best deal flow across Europe. The participation of the VCT alongside co-branded Molten Ventures plc investment partners enable the VCT to obtain access to private technology company fundraisings that are rarely accessible to individual investors.

 

As at 30 September 2023, Molten Ventures VCT had a diverse portfolio and has invested over £45 million into 39 technology companies. We invest across four sectors: Enterprise Technology, Hardware and Deeptech, Consumer Technology, and Digital Health and Wellness, with highly experienced partners constantly looking for new opportunities in each. We look for high-growth companies operating in new markets, with aspirations for global expansion, strong IP, powerful technology, and strong management teams to deliver success. We also look for businesses with the potential to generate strong margins to ensure rapid, sustainable growth in substantial addressable markets.

 

The VCT therefore gives investors a rare opportunity to invest in private companies, in their high growth phase, that have the possibility to be breakthroughs in their field and become attractive candidates for acquisition, or IPO, with valuations from $50 million to $1 billion+.

 

For more information, go to https://investors.moltenventures.com/investor-relations/vct

 

 

 

1 May 2024

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
ACQEFLFBZELBBBV
12
Date   Source Headline
1st May 20244:11 pmRNSPortfolio Update
1st May 20249:36 amRNSTotal Voting Rights
24th Apr 20243:31 pmRNSIssue of Equity
15th Apr 20246:04 pmRNSTransaction in Own Shares
23rd Jan 202412:34 pmGNWDirectorate change
29th Dec 202310:03 amGNWForm 8.3 - [MOLTEN VENTURES PLC - 28 12 2023] - (CGAML)
14th Dec 202312:35 pmGNWHalf-year report
4th Dec 20234:39 pmGNWCorrection: Form 8.3 - MOLTEN VENTURES PLC
29th Nov 20232:05 pmGNWForm 8.3 - MOLTEN VENTURES PLC
3rd Oct 20235:27 pmGNWPublication of Prospectus
2nd Oct 202312:59 pmGNWTotal Voting Rights
29th Sep 20235:29 pmGNWIssue of Equity (DRIS)
28th Sep 20233:28 pmGNWNet Asset Value(s)
20th Sep 20233:44 pmGNWResult of AGM
18th Sep 20235:51 pmGNWPurchase and transfer of securities by Elderstreet Investments Limited
31st Aug 20235:50 pmGNWTotal Voting Rights
9th Aug 20231:22 pmGNWTransaction in Own Shares
1st Aug 202310:55 amGNWForthcoming Dividend – DRIS Election Date
31st Jul 20234:40 pmGNWFinal Results
31st Jul 20234:20 pmGNWFinal Results
2nd May 202310:51 amGNWTotal Voting Rights
11th Apr 20234:46 pmGNWIssue of Equity
6th Apr 20235:47 pmGNWTransaction in Own Shares
6th Apr 20235:14 pmGNWIssue of Equity (DRIS)
3rd Apr 20233:59 pmGNWIssue of Equity
31st Mar 20236:13 pmGNWTotal Voting Rights
16th Mar 20235:06 pmGNWUpdate regarding Silicon Valley Bank
14th Feb 202311:38 amGNWPublication of a supplementary prospectus
14th Feb 202310:48 amGNWNet Asset Value and Dividend Outlook
6th Feb 20236:22 pmGNWOffer for Subscription Closed
3rd Jan 20233:04 pmGNWDividend payment date correction
23rd Dec 20221:26 pmGNWShare Buybacks
23rd Dec 20221:24 pmGNWFundraising Update
9th Dec 202211:28 amGNWHalf-year report
1st Dec 20226:09 pmGNWResult of General Meeting
30th Sep 20225:22 pmGNWTotal Voting Rights
30th Sep 20225:21 pmGNWTransaction in Own Shares
13th Sep 20225:59 pmGNWIntention To Launch Offer for Subscription
1st Sep 202210:09 amGNWTotal Voting Rights
26th Aug 202211:29 amGNWIssue of Equity (DRIS)
18th Aug 20224:46 pmGNWResult of AGM
1st Aug 202212:06 pmGNWTotal Voting Rights
26th Jul 20224:07 pmGNWTransaction in Own Shares and Total Voting Rights
18th Jul 20227:00 amGNWFinal Results
18th May 20227:00 amGNWPortfolio Update
3rd May 202210:31 amGNWTotal Voting rights
8th Apr 20224:52 pmGNWIssue of Equity
1st Apr 20225:35 pmGNWCorrection: Issue of Equity
1st Apr 20225:18 pmGNWIssue of Equity
31st Mar 20225:49 pmGNWTotal Voting Rights
12

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.